Display options
Cite
Sonbol MB, Halfdanarson TR. Ipilimumab and Nivolumab in Rare Tumors S1609: Neuroendocrine-Letter. Clin Cancer Res. 2020;26(10):2433doi: 10.1158/1078-0432.CCR-20-0443.
Sonbol, M. B., & Halfdanarson, T. R. (2020). Ipilimumab and Nivolumab in Rare Tumors S1609: Neuroendocrine-Letter. Clinical cancer research : an official journal of the American Association for Cancer Research, 26(10), 2433. https://doi.org/10.1158/1078-0432.CCR-20-0443
Sonbol, Mohamad B, and Halfdanarson, Thorvardur R. "Ipilimumab and Nivolumab in Rare Tumors S1609: Neuroendocrine-Letter." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 26,10 (2020): 2433. doi: https://doi.org/10.1158/1078-0432.CCR-20-0443
Sonbol MB, Halfdanarson TR. Ipilimumab and Nivolumab in Rare Tumors S1609: Neuroendocrine-Letter. Clin Cancer Res. 2020 May 15;26(10):2433. doi: 10.1158/1078-0432.CCR-20-0443. PMID: 32414760.
Copy Download .nbib Format: NLM
Share it on

Clin Cancer Res. 2020 May 15;26(10):2433. doi: 10.1158/1078-0432.CCR-20-0443.

Ipilimumab and Nivolumab in Rare Tumors S1609: Neuroendocrine-Letter.

Clinical cancer research : an official journal of the American Association for Cancer Research

Mohamad B Sonbol, Thorvardur R Halfdanarson

Affiliations

  1. Mayo Clinic Cancer Center, Phoenix, Arizona. [email protected].
  2. Mayo Clinic Cancer Center, Rochester, Minnesota.

PMID: 32414760 DOI: 10.1158/1078-0432.CCR-20-0443

[No abstract available.]

Substances

MeSH terms

Publication Types